Symmetry Medical Inc. has announced that its subsidiary, Symmetry Surgical, has entered into an exclusive distribution agreement with MTG Medical Technologies (MTG), subsidiary of Neuro-Competence, in Germany, Austria, Switzerland, Czech Republic, Hungary and Slovakia. Under terms of the agreement, MTG will distribute Symmetry Surgical’s portfolio of surgical instruments, which includes all brands and products of the recently acquired Codman surgical instruments portfolio from Johnson and Johnson.
Symmetry Partnering With MTG Medical
1 min read Premium comments
Secondary
“Partnering with MTG and bringing the Symmetry Surgical portfolio to Europe is an exciting milestone in expanding our global presence, ” said Chris Huntington, chief operating officer of Symmetry Surgical, in the October 31, 2012 news release. “Their expertise and mission align with our own values, which are focused on improving patient care and outcomes. We look forward to working with MTG to achieve strong growth in these key markets as we continue our expansion into other European countries in the coming months.”
Huntington told OTW,
Through our partnerships with MTG Medical Technologies and a growing number of strategic distribution partners throughout Europe, Asia Pacific, South America and North America, we are committed to giving healthcare professionals around the world access to new and innovative surgical instruments that can benefit their patients. We are investing in the research and development of new surgical instruments – monitoring the marketplace and working with top surgeons and industry leaders to broaden our already diverse portfolio with medical devices that meet real-world needs.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.